<DOC>
	<DOC>NCT00765687</DOC>
	<brief_summary>A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.</brief_summary>
	<brief_title>Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1. Age &gt;18, either sex 2. Histologically confirmed nonsmall cell cancer 3. One bone metastasis at least confirmed by image(X ray,CT or others) 4. Without receiving zoledronic acid 5. Life expectancy &gt; 6 M 6. ECOG &lt;= 2 7. Signed ICF 1. Women who are pregnant or in lactation 2. Patients with hyperostosis 3. with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled 4. Previous or current treatment with any other bisphosphonates, bone protecting, cytotoxic or targeted therapy 5. Severe comorbidity of any type that may interfere with assessment of the patient for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>